Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good W@G Farooq
With the various FDA decision announced this week, we are experiencing an influx of money from those events. I hope it continues and I would like to the $1.50 range by next Thursday also.
Very good W@G Ray. I have the close at 64.06 but maybe off by a penny.
W@G2 03/07/12 for a 03/09/12 close
61.89 Kookiekook
While technicals are of value and can be very useful, their value with stocks that have binary events pending are limited in my opinion.
TLON has two pending binary events, the first on March 21st with the FDA Panel hearing and the 2nd in May with the FDA decision on the PDUFA. A favorable vote from the hearing can easily double the price of this stock while a negative vote can easily see it selling around $0.50 to $0.60. This will occur in direct response to the panel hearing (and disclosure of the panel's iternary and questions) and essentially occur overnight. There is no way technicals can predict that action.
Please Note:
I did not state that NGSX will continue to persue this as a chronic pain reliever with HIV. I do believe that the FDA will issue a CRL, and the company will issue a response stating that will continue to study Casparin as a chronic pain reliever, but at the same time note that with the acculmuated data are intending to pursue the use Casparin as an acute pain reliever and expect to either commence a phase III study shortly or depending on how much data is available submit a new NDA shortly.
Of course, I am also persuming that NGSX management has the foresight to have a decent response ready. We shall see. But I beleive "good" management should always have anticipated things that could negatively affect the company and have a countering plan in place.
It may not hit a low of $0.40 but it will be close. It will hit a low in the low $0.40's (probably .42 or .41) and my guess it will stabilize in the high $.04's ($.47 or $.48) and stay about there for about 3 weeks before moving much depending on how the company responds to the CLR I expect them to recieve.
While the company is still hopeful for FDA approval, that is unlikely, but they should have a game-plan in place on how to handle the anticipated CRL and be able to put together a response fairly quickly.
W@G1 03/05/12 for a 03/07/12 close
64.36 Kookiekook
64.00 rayrohn
Good W@G Farooq
Thank you Ray and Paul
Bernanke opens mouth and stock market falls. Just like normal. Wish he would go away, his policies have done nothing for the economy and it about time for someone else to take the reigns.
W@G2 02/29/12 for a 03/02/12 close
64.36 Kookiekook
W@G1 02/27/12 for a 02/29/12 close
64.36 Kookiekook
Sorry I find that hard to buy. If they sold the shares in the treasury it would bring in over $300million (at $1/share) Raising the A/S gives them the potential to raise slightly over $500 million.
But if $300 million isn't enough to launch the drug, they have a serious problem and the drug would have priced out the market to make-up the expense.
A/S = authorized shares.
What I do not understand is why they believe they need to increase the A/S. According to the last quarterly report they have an A/S of 350 million shares with less than 10% outstanding. Raising the A/S does nothing but raise a potential red flag IMO. Also the recent R/S should have negated the need for this.
Nice correction.
Nice correction.
Sorry to bust your bubble, but even if KIK smholton and Skillz gave up those amount to you, you would still be only be in third.
smholton- 43.45
KiK - 42.21
kozuh - 38.91
SKILLZ - 31.59
Thank you Ray and Paul
Thank you Ray and Paul
Thank you for posting this news article. It seemd to reinforce that things are proceeding well.
I agree DO NOT ABANDON HOPE.
The drug usage under review (and which the panel considered) was as a pain reliever for AIDS patients. I am assuming the pain associated with AIDS is chronic in nature, versus acute (in other words long term versus short term). Unfortunately the testing showed it more effective at 30 minutes than existing pain relievers but not more effective at 60 minutes (therefore more effective against acute pain versus chronic pain). While not fully understanding the pain reliever market, I would anticipate the strong possibility of a new NDA centering this around acute pain and using at least some of the trial data generated for the current FDA application thus hopefully reducing some trial time.
Good W@G Farooq
W@G2 02/22/12 for a 02/24/12 close
63.89 Kookiekook
Holiday monday so this is a 2 day W@G
W@G1 02/21/12 for a 02/22/12 close
64.19 Kookiekook
63.80 Never96
Good W@G Farooq
Good W@G Farooq
Sunspotter
I am glad you find it entertaining that Aspacio has chosen to keep us informed of the current happenings with MKRO/Nissi.
While you see it as supporting your contention that this is a scam, I see it as an another move and as evidence that the "new" management has a desire to increase current shareholder value by establishing a fully reporting and transparent company.
W@G2 02/15/12 for a 02/17/12 close
62.36 Kookiekook
W@G1 02/13/12 for a 02/15/12 close
62.47 Kookiekook
62.30 Never96
Thank you Paul
Thank you Ray
Might have been a little overzealous in my $0.40 prediction, but if you could have picked up at today's low of $0.50 and sold an hour later at $0.67 you could have a made a little profit of about 30-35% depeding on brokerage charges, which isn't bad for a quick turn-around.
Honestly I do not remember trading being halted in the past for reviews but both NGSX and ASTX were halted while the review was in progress today (ASTX's review is complete and that stock is trading now).
This maybe something new in effort to curb "insider" trading. Something the FDA has been having problems with.
It is halted because its PDUFA is under review by an FDA Committee today. The results of that review should be known later today and trading will resume tommorrow.
I would expect a PR in the morning Pre-market opening. The stock will be trading.
Another positive move to get this ship righted. Hopefully, 2nd and 3rd quarter financials will follow shortly.
It should be noted that the financials are for the 1st quarter of 2011 and do not include any funds, or assets from Nissi Mining as this is still pre-merger in time frame. We will not see any assets etc from Nissi until the third quarter report is released.
Thanks Paul
Thanks Ray
There is a big difference in NASDAQ exchange, where many good companies are listed including Apple and Intel and the NASDAQ OTC.
NASDAQ upkeeps the OTC market and provides some electronic platform but it is not the NASDAQ exchange. The requirements for listing on the NASDAQ exchange are much more strigent than the requirements for a stock to be listed as OTC.